Freenome, a biomarker discovery platform, and retail pharmacy giant Walgreens have entered a multi-year partnership to advance clinical studies focused on the early detection of cancer through the use of Freenome's blood-based tests.

Walgreens will leverage its national presence, patient insights, and infrastructure to engage diverse patient populations in Freenome's multi-cancer research program. The primary objective of this collaboration is to enhance health outcomes and promote advancements in oncology by identifying cancers at an early and treatable stage.

To facilitate these efforts Walgreens, in collaboration with technology provider Curebase, will recruit patients for Freenome's Sanderson Study and deliver targeted outreach through various channels. This study specifically focuses on evaluating blood-based methods for early cancer detection across different types of tumors, with an anticipated enrollment of approximately 8,000 participants.

In addition to patient recruitment, the partnership encompasses the development of risk-prediction models, population health software, and the collection of real-world data. In addition to patient recruitment, the partnership encompasses the development of risk-prediction models, population health software, and the collection of real-world data. These endeavors aim to contribute to the advancement of cancer detection research and the improvement of overall cancer care.